MX2022011206A - Composiciones farmaceuticas de sales de ester de colina de acido lipoico y metodos de tratamiento usando las mismas. - Google Patents

Composiciones farmaceuticas de sales de ester de colina de acido lipoico y metodos de tratamiento usando las mismas.

Info

Publication number
MX2022011206A
MX2022011206A MX2022011206A MX2022011206A MX2022011206A MX 2022011206 A MX2022011206 A MX 2022011206A MX 2022011206 A MX2022011206 A MX 2022011206A MX 2022011206 A MX2022011206 A MX 2022011206A MX 2022011206 A MX2022011206 A MX 2022011206A
Authority
MX
Mexico
Prior art keywords
methods
pharmaceutical compositions
lipoic acid
treatment
same
Prior art date
Application number
MX2022011206A
Other languages
English (en)
Spanish (es)
Inventor
Dietmar Flubacher
Zaixing Li
Christoph Bucher
Liladhar Murlidhar Waykole
Tingying Zhu
Jeremiah Douglas Foutch
Malay Ghosh
Johannes Franz Kluge
Cale Ry Mcalister
Jens Soren Worthmann
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2022011206A publication Critical patent/MX2022011206A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D339/00Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02Five-membered rings
    • C07D339/04Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/724Cyclodextrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/10Ophthalmic agents for accommodation disorders, e.g. myopia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/28Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63Esters of sulfonic acids
    • C07C309/72Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
MX2022011206A 2020-03-13 2021-03-12 Composiciones farmaceuticas de sales de ester de colina de acido lipoico y metodos de tratamiento usando las mismas. MX2022011206A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020079271 2020-03-13
US202063013836P 2020-04-22 2020-04-22
PCT/IB2021/052092 WO2021181361A1 (en) 2020-03-13 2021-03-12 Pharmaceutical compositions of lipoic acid choline ester salts and methods of treatment using same

Publications (1)

Publication Number Publication Date
MX2022011206A true MX2022011206A (es) 2022-09-19

Family

ID=75108681

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011206A MX2022011206A (es) 2020-03-13 2021-03-12 Composiciones farmaceuticas de sales de ester de colina de acido lipoico y metodos de tratamiento usando las mismas.

Country Status (18)

Country Link
US (2) US11135239B1 (enExample)
EP (1) EP4118079A1 (enExample)
JP (2) JP7041298B2 (enExample)
KR (1) KR20220146561A (enExample)
CN (2) CN113387923A (enExample)
AU (1) AU2021235563A1 (enExample)
BR (1) BR112022018043A2 (enExample)
CA (1) CA3175077A1 (enExample)
CO (1) CO2022012653A2 (enExample)
CR (1) CR20220449A (enExample)
DO (1) DOP2022000179A (enExample)
EC (1) ECSP22069611A (enExample)
IL (1) IL295378A (enExample)
JO (1) JOP20220211A1 (enExample)
MX (1) MX2022011206A (enExample)
PE (1) PE20230242A1 (enExample)
TW (1) TWI768760B (enExample)
WO (1) WO2021181361A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI896143B (zh) 2023-05-24 2025-09-01 溫州醫科大學附屬眼視光醫院 一種有效延緩及治療近視的藥物組合物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5520920A (en) 1978-07-31 1980-02-14 Honda Motor Co Ltd Device for absorbing twisting vibration of drive system
US8647612B2 (en) 2008-03-05 2014-02-11 Encore Health, Llc Dithiol compounds, derivatives, and treatment of presbyopia
MY144753A (en) * 2004-04-27 2011-10-31 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
DE102006062599B4 (de) 2006-12-29 2018-03-08 Endress + Hauser Gmbh + Co. Kg Opto-elektronische Vorrichtung zur Übertragung eines elektrischen Signals und deren Verwendung
WO2009038656A1 (en) 2007-09-17 2009-03-26 Kosta Steliou Mitochondria-targeting antioxidant therapeutics
WO2009111635A2 (en) 2008-03-05 2009-09-11 Encore Health, Llc Dithiol compounds, derivatives, and uses therefor
US9044439B2 (en) 2008-03-05 2015-06-02 Encore Health, Llc Low dose lipoic and pharmaceutical compositions and methods
EP3069612A3 (en) * 2009-06-15 2016-10-19 Encore Health, LLC Dithiol compounds, derivatives, and uses therefor
ES2579173T3 (es) 2009-06-15 2016-08-05 Encore Health, Llc Ésteres de colina para tratar presbicia y cataratas
BR112016020181A8 (pt) 2014-03-03 2021-06-29 Encore Vision Inc composições de ácido lipoico éster colina e métodos de uso.
WO2016126662A1 (en) 2015-02-03 2016-08-11 Kardiatonos, Inc. Compounds for the prevention and treatment of vascular disease
WO2016164534A1 (en) 2015-04-09 2016-10-13 Kardiatonos, Inc. Methods and compositions for reversing disruption of the glycocalyx, inflammation, and oxidative damage
CA3022351A1 (en) 2015-04-29 2016-11-03 Kardiatonos, Inc. Methods and compositions for reversing disruption of the glycocalyx, inflammation, and oxidative damage
WO2017053646A1 (en) * 2015-09-24 2017-03-30 Encore Vision, Inc. Lipoic acid choline ester compositions and methods to generate biocompatible ophthalmic formulations
JOP20190057A1 (ar) 2016-09-23 2019-03-24 Encore Vision Inc تركيبات استر كولين حمض الليبويك وطرق تثبيتها إلى منتجات عقار ذات صلة دوائية
CN106967044B (zh) 2017-05-12 2019-02-22 苏州富士莱医药股份有限公司 制备r-硫辛酸胆碱酯卤化物的方法
CN107089967A (zh) 2017-05-12 2017-08-25 苏州富士莱医药股份有限公司 一种r‑硫辛酸胆碱酯卤化物的制备方法
SG11202006492SA (en) * 2018-02-05 2020-08-28 Cellix Bio Private Ltd Combination of an antimuscarinic or an anticholinergic agent and lipoic acid and uses thereof
US11158871B2 (en) 2018-07-18 2021-10-26 GM Global Technology Operations LLC Fuel cell assembly and a vehicle that utilizes the fuel cell assembly
US11985964B2 (en) 2018-08-03 2024-05-21 Kevin F Lohmeier Fishing rod holder
CN108822077A (zh) 2018-08-07 2018-11-16 苏州富士莱医药股份有限公司 一种r-硫辛酸胆碱酯卤化物的精制方法
CN108586429A (zh) 2018-08-07 2018-09-28 苏州富士莱医药股份有限公司 R-硫辛酸胆碱酯卤化物的纯化精制方法

Also Published As

Publication number Publication date
TWI768760B (zh) 2022-06-21
US20210283171A1 (en) 2021-09-16
CR20220449A (es) 2022-10-12
JP2022058376A (ja) 2022-04-12
US11590158B2 (en) 2023-02-28
JP2021147392A (ja) 2021-09-27
AU2021235563A1 (en) 2022-09-22
TW202140435A (zh) 2021-11-01
US20210393671A1 (en) 2021-12-23
DOP2022000179A (es) 2022-09-30
EP4118079A1 (en) 2023-01-18
CN115279745A (zh) 2022-11-01
CA3175077A1 (en) 2021-09-16
CN113387923A (zh) 2021-09-14
PE20230242A1 (es) 2023-02-07
JP7041298B2 (ja) 2022-03-23
KR20220146561A (ko) 2022-11-01
US11135239B1 (en) 2021-10-05
ECSP22069611A (es) 2022-10-31
JOP20220211A1 (ar) 2023-01-30
WO2021181361A1 (en) 2021-09-16
BR112022018043A2 (pt) 2022-10-18
CO2022012653A2 (es) 2022-09-09
IL295378A (en) 2022-10-01

Similar Documents

Publication Publication Date Title
MX2021009276A (es) Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibidora sobre cdk2.
MX2022003984A (es) Compuestos heterociclicos antivirales.
MX2021009806A (es) Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos.
PH12020551578A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
MX389965B (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos
MX389597B (es) Inhibidores de cdk2/4/6 de piridopirimidinona.
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
BR112012023421A2 (pt) composição farmacêutica para tratamento de aumento de pressão intraocular
EA201792214A1 (ru) Соединения замещенного хиназолина
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
BR112015022785A2 (pt) composto; composição farmacêutica; kit ou artigo farmacêutico embalado; método de inibição de uma arginina metil transferase (rmt); método de modulação da expressão genética; método de modulação da transcrição; e método de tratamento de um distúrbio mediado por rmt
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
BR112016028876A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos.
WO2023078333A8 (zh) 一种取代的苯丙酸衍生物及其用途
MX2021002382A (es) Sales y formas cristalinas de modulador alosterico positivo gabaa.
MX2019013562A (es) Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos.
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
JOP20200100A1 (ar) مشتقات بيرازولو-بيرولو-بيريميدين-ديون جديدة كمثبِّطات لـ p2x3
CA2902116C (en) Pyrrolopyridine derivatives and their use as inhibitors of ssao activity
ZA202107777B (en) Voruciclib polymorphs and methods of making and using thereof
MX2020001875A (es) Forma polimorfica de tg02.
MX389581B (es) Compuestos que contienen nitrogeno sustituido.
PH12021551412A1 (en) Ursodeoxycholic acid-containing agent for treating or preventing presbyopia
MX2023014776A (es) Sales de sulcardina.